Insider Buying: TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Purchases 24,000 Shares of Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO James Emmett Young acquired 24,000 shares of TriSalus Life Sciences stock in a transaction that occurred on Monday, January 27th. The shares were purchased at an average price of $5.40 per share, with a total value of $129,600.00. Following the transaction, the chief financial officer now owns 24,000 shares of the company’s stock, valued at $129,600. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

TriSalus Life Sciences Trading Up 4.5 %

Shares of TriSalus Life Sciences stock opened at $5.11 on Friday. The stock has a 50 day moving average of $4.57 and a 200 day moving average of $4.75. TriSalus Life Sciences, Inc. has a 12 month low of $3.50 and a 12 month high of $10.42. The firm has a market cap of $155.80 million, a PE ratio of -2.05 and a beta of 0.51.

Hedge Funds Weigh In On TriSalus Life Sciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in TriSalus Life Sciences by 45.4% during the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after buying an additional 62,542 shares during the last quarter. MSD Partners L.P. bought a new position in TriSalus Life Sciences during the third quarter valued at approximately $184,000. Walleye Capital LLC bought a new position in TriSalus Life Sciences during the third quarter valued at approximately $66,000. Virtu Financial LLC bought a new position in TriSalus Life Sciences during the third quarter valued at approximately $92,000. Finally, Vestcor Inc bought a new position in TriSalus Life Sciences during the third quarter valued at approximately $108,000. 2.58% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on TLSI shares. Roth Mkm reiterated a “buy” rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Canaccord Genuity Group reduced their price target on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Finally, Northland Securities initiated coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target for the company. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $11.79.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.